Affiliations
AffiliationsItem in Clipboard
One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer RiskKarla Kerlikowske et al. Cancer Epidemiol Biomarkers Prev. 2015 Jun.
doi: 10.1158/1055-9965.EPI-15-0035. Epub 2015 Mar 30. AffiliationsItem in Clipboard
AbstractBackground: One measure of Breast Imaging Reporting and Data System (BI-RADS) breast density improves 5-year breast cancer risk prediction, but the value of sequential measures is unknown. We determined whether two BI-RADS density measures improve the predictive accuracy of the Breast Cancer Surveillance Consortium 5-year risk model compared with one measure.
Methods: We included 722,654 women of ages 35 to 74 years with two mammograms with BI-RADS density measures on average 1.8 years apart; 13,715 developed invasive breast cancer. We used Cox regression to estimate the relative hazards of breast cancer for age, race/ethnicity, family history of breast cancer, history of breast biopsy, and one or two density measures. We developed a risk prediction model by combining these estimates with 2000-2010 Surveillance, Epidemiology, and End Results incidence and 2010 vital statistics for competing risk of death.
Results: The two-measure density model had marginally greater discriminatory accuracy than the one-measure model (AUC, 0.640 vs. 0.635). Of 18.6% of women (134,404 of 722,654) who decreased density categories, 15.4% (20,741 of 134,404) of women whose density decreased from heterogeneously or extremely dense to a lower density category with one other risk factor had a clinically meaningful increase in 5-year risk from <1.67% with the one-density model to ≥1.67% with the two-density model.
Conclusion: The two-density model has similar overall discrimination to the one-density model for predicting 5-year breast cancer risk and improves risk classification for women with risk factors and a decrease in density.
Impact: A two-density model should be considered for women whose density decreases when calculating breast cancer risk.
©2015 American Association for Cancer Research.
Conflict of interest statementDisclosure of Potential Conflicts of Interest:
The authors declare that they have no conflicts of interests to disclose.
FiguresFigure 1
a–1d. Cumulative incidence of invasive…
Figure 1
a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure…
Figure 1a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure 1a; almost entirely fatty breasts, 1b; scattered fibroglandular densities, 1c; heterogeneously dense, 1d; extremely dense) and previous density measure for the 14 combinations of BI-RADS density over 10 years of follow-up. The sold horizontal line represents a cumulative incidence of 1.67%. Density combinations d:a and a:d were excluded from the figure because of small numbers.
Figure 1
a–1d. Cumulative incidence of invasive…
Figure 1
a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure…
Figure 1a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure 1a; almost entirely fatty breasts, 1b; scattered fibroglandular densities, 1c; heterogeneously dense, 1d; extremely dense) and previous density measure for the 14 combinations of BI-RADS density over 10 years of follow-up. The sold horizontal line represents a cumulative incidence of 1.67%. Density combinations d:a and a:d were excluded from the figure because of small numbers.
Figure 1
a–1d. Cumulative incidence of invasive…
Figure 1
a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure…
Figure 1a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure 1a; almost entirely fatty breasts, 1b; scattered fibroglandular densities, 1c; heterogeneously dense, 1d; extremely dense) and previous density measure for the 14 combinations of BI-RADS density over 10 years of follow-up. The sold horizontal line represents a cumulative incidence of 1.67%. Density combinations d:a and a:d were excluded from the figure because of small numbers.
Figure 1
a–1d. Cumulative incidence of invasive…
Figure 1
a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure…
Figure 1a–1d. Cumulative incidence of invasive cancer by most recent BI-RADS density measure (Figure 1a; almost entirely fatty breasts, 1b; scattered fibroglandular densities, 1c; heterogeneously dense, 1d; extremely dense) and previous density measure for the 14 combinations of BI-RADS density over 10 years of follow-up. The sold horizontal line represents a cumulative incidence of 1.67%. Density combinations d:a and a:d were excluded from the figure because of small numbers.
Figure 2
a–2d . Distribution of 5-year…
Figure 2
a–2d . Distribution of 5-year and 10-year risk for women with the one-measure…
Figure 2a–2d. Distribution of 5-year and 10-year risk for women with the one-measure (2a and 2b) and two-measure density models (2c and 2d).
Figure 2
a–2d . Distribution of 5-year…
Figure 2
a–2d . Distribution of 5-year and 10-year risk for women with the one-measure…
Figure 2a–2d. Distribution of 5-year and 10-year risk for women with the one-measure (2a and 2b) and two-measure density models (2c and 2d).
Figure 2
a–2d . Distribution of 5-year…
Figure 2
a–2d . Distribution of 5-year and 10-year risk for women with the one-measure…
Figure 2a–2d. Distribution of 5-year and 10-year risk for women with the one-measure (2a and 2b) and two-measure density models (2c and 2d).
Figure 2
a–2d . Distribution of 5-year…
Figure 2
a–2d . Distribution of 5-year and 10-year risk for women with the one-measure…
Figure 2a–2d. Distribution of 5-year and 10-year risk for women with the one-measure (2a and 2b) and two-measure density models (2c and 2d).
Similar articlesKerlikowske K, Ichikawa L, Miglioretti DL, Buist DS, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R; National Institutes of Health Breast Cancer Surveillance Consortium. Kerlikowske K, et al. J Natl Cancer Inst. 2007 Mar 7;99(5):386-95. doi: 10.1093/jnci/djk066. J Natl Cancer Inst. 2007. PMID: 17341730
Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Tice JA, et al. J Clin Oncol. 2015 Oct 1;33(28):3137-43. doi: 10.1200/JCO.2015.60.8869. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282663 Free PMC article.
Kerlikowske K, Zhu W, Tosteson AN, Sprague BL, Tice JA, Lehman CD, Miglioretti DL; Breast Cancer Surveillance Consortium. Kerlikowske K, et al. Ann Intern Med. 2015 May 19;162(10):673-81. doi: 10.7326/M14-1465. Ann Intern Med. 2015. PMID: 25984843 Free PMC article.
Kerlikowske K, Ma L, Scott CG, Mahmoudzadeh AP, Jensen MR, Sprague BL, Henderson LM, Pankratz VS, Cummings SR, Miglioretti DL, Vachon CM, Shepherd JA. Kerlikowske K, et al. Breast Cancer Res. 2017 Aug 22;19(1):97. doi: 10.1186/s13058-017-0887-5. Breast Cancer Res. 2017. PMID: 28830497 Free PMC article.
Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL. Nelson HD, et al. Ann Intern Med. 2012 May 1;156(9):635-48. doi: 10.7326/0003-4819-156-9-201205010-00006. Ann Intern Med. 2012. PMID: 22547473 Free PMC article. Review.
Anandarajah A, Chen Y, Stoll C, Hardi A, Jiang S, Colditz GA. Anandarajah A, et al. Cancer Causes Control. 2023 Nov;34(11):939-948. doi: 10.1007/s10552-023-01739-2. Epub 2023 Jun 20. Cancer Causes Control. 2023. PMID: 37340148 Free PMC article. Review.
Atakpa EC, Buist DSM, Aiello Bowles EJ, Cuzick J, Brentnall AR. Atakpa EC, et al. Breast Cancer Res. 2023 Nov 24;25(1):147. doi: 10.1186/s13058-023-01744-y. Breast Cancer Res. 2023. PMID: 38001476 Free PMC article.
Mullooly M, Fan S, Pfeiffer RM, Bowles EA, Duggan MA, Falk RT, Richert-Boe K, Glass AG, Kimes TM, Figueroa JD, Rohan TE, Abubakar M, Gierach GL. Mullooly M, et al. Breast Cancer Res. 2024 Mar 26;26(1):52. doi: 10.1186/s13058-024-01764-2. Breast Cancer Res. 2024. PMID: 38532516 Free PMC article.
Kerlikowske K, Chen S, Bissell MCS, Lee CI, Tice JA, Sprague BL, Miglioretti DL. Kerlikowske K, et al. JAMA Oncol. 2024 Feb 1;10(2):167-175. doi: 10.1001/jamaoncol.2023.5242. JAMA Oncol. 2024. PMID: 38060241 Free PMC article.
Abdolell M, Tsuruda KM, Brown P, Caines JS, Iles SE. Abdolell M, et al. Br J Radiol. 2017 Oct;90(1078):20170307. doi: 10.1259/bjr.20170307. Epub 2017 Sep 8. Br J Radiol. 2017. PMID: 28707989 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3